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INTRODUCTION 
Drug abuse is characterized by improper repeated use of drugs to seek outcomes 
such as  pleasure, stress relief and an altered reality.1 It can lead to addiction, a severe 
form of substance use disorder (SUD) in which a person’s drug habits worsen and they 
become unable to control the impulse to use drugs despite knowing the negative 
consequences.1 In addition to drug seeking behavior, brain function also changes 
affecting the natural inhibition and reward centers. Use of and addiction to alcohol, 
nicotine, and illicit drugs costs the Nation more than $740 billion a year related to 
healthcare, crime, and lost productivity.1 Whether a person will abuse drugs or become 
addicted is influenced by multiple factors; the more risk factors a person has, the greater 
the chance. Risk factors can be either environmental or biological such as mental 
disorders.1 Mental disorders affect a significant amount of people and have a large impact 
on public health. These disorders impair an individual’s normal function and make it 
difficult to complete daily activities generally by causing negative changes in mood, 
thought or behavior. Substance use disorders often co-exist with mental illnesses such 
as depression. Sometimes SUD precede mental illness or vice-versa. The approximate 
percentages of adults who use illicit drugs are higher among those with mental illness 
(86.1%) compared with those without any mental illness (15.7%).2 Three pathways 
contribute to the comorbidity between SUD and mental illnesses.3 One main pathway is 
through common risk factors namely genetic and epigenetic vulnerabilities, problems in 
similar brain areas, early exposure or trauma that can cause both SUD and other mental 
illnesses.3   Secondly, individuals with mental disorders often use drugs to self-medicate 
in order to alleviate the negative symptoms of their mental illness and by doing so develop 
an SUD. Lastly, drug use in people with an underlying predisposition of a mental illness 
can produce changes in brain structure and function that may cause them to develop that 
mental illness.3   
PSYCHEDELICS, THE BRAIN AND HEALING  
 Hallucinogens (“all-arounders”) or Psychedelics (“mind manifesting”) include 
substances that produce alterations in perception, sensations of space and time and 
emotional states, in other words, they alter a person’s awareness of their surroundings 
as well as their thoughts and feelings.4 Throughout history numerous cultures have used 
these substances for religious rituals to facilitate spiritual experiences and more recently, 
people report using them for social or recreational purposes. In the 1950s and 1960s, 
LSD-lysergic acid diethylamide- was researched and achieved major breakthrough 
treatments in the field of psychiatry.5  Albert Hofmann, a swiss chemist,  first synthesized 
LSD in 1938 while doing a research program that was searching for medically useful 
ergot-alkaloid derivatives.6 Five years later, Hofmann discovered its psychedelic 
properties while accidentally ingesting the chemical.6 In his 1979 autobiography, My 
Problem Child, Hofmann describes how he became restless and dizzy when he 
accidentally ingested LSD while making it and “ perceived an uninterrupted stream of 
fantastic pictures, extraordinary shapes with intense , kaleidoscopic play of colors” for 
approximately two hours.7 The next day he intentionally ingested 0.25 milligram of the 
acid to confirm that it caused the symptoms he had experienced.7 Interest in psychedelic 
substances for their medicinal and transformational benefits first arose when the profound 
effects of LSD on the human psyche led neuroscientists to realize that there was a 
connection between chemistry and behavior.6 After the discovery of LSD, within a few 
years serotonin was discovered in the brain. By looking at those two structures, 
researchers realized that LSD had a similar chemical template as serotonin, which was 
found in the brain and since LSD produced dramatic behavioral changes, they realized 
maybe there was a relationship between brain serotonin and behavior. This neuroscience 
research paved the way for the selective serotonin reuptake inhibitors [SSRIs] we use 
now for treating depression.6 Leading scientists in psychedelic research provide data that 
some psychedelic medicines when administered by proper protocols and informed by 
research can cause altered states of consciousness that facilitate brilliant creativity and 
psychophysical healing.6 What is the connection? Three known monoamine 
neurotransmitters exist in the brain: dopamine, norepinephrine and serotonin. There are 
fifteen different types of receptors known for serotonin whereas for dopamine and 
norepinephrine there are far less. The serotonin neurons project into all parts of the cortex 
and higher areas of the brain. They are involved in emotions such as anger, rage, hunger, 
sex drive, cognition, depression, mood and more. All of the psychedelics interact or 
activate the serotonin 5-HT2A receptor.6 Currently, serotonergic psychedelics, particularly 
psilocybin (active compound in ‘’magic mushrooms”) are being researched as potential 
treatments for different psychiatric disorders.7 
PSILOCYBIN AND DRUG ABUSE  
Psilocybin mushrooms contain the psychedelic compounds psilocybin, psilocin 
and baeocystin. Upon oral administration, psilocybin is metabolized into psilocin (4-
hydroxy-N,N- dimethyltryptamine) which acts as a 5-HT agonist and has high affinity for 
the 5-HT2A receptor subtype responsible for the psychotropic effects. After ingestion a 
person might feel effects like a sense of euphoria, alterations in thinking, visualizations, 
altered sense of time, synesthesia and spiritual experiences.  According to The National 
Institute on Drug Abuse (NIDA), the potential for magic mushrooms to produce long-term 
detrimental effects is not fully known.8 Under the influence of psilocybin an individual’s 
logic and reasoning abilities are compromised, therefore, set and setting are crucial 
factors in the experience as the individual can pose a threat to him or herself and others. 
Negative experiences known as “bad trips” can have lasting effects on the user such as 
developing hallucinogen persisting perception disorder. These people may suffer from 
flashbacks or re-experience the psilocybin intoxication even when they have abstained 
from magic mushroom use for a long period. Unlike other drugs of abuse, long-term 
psilocybin use does not lead to physical dependence or withdrawal symptoms, but chronic 
users may develop tolerance which means that they need increased doses of psilocybin 
to achieve the level of intoxication they are seeking.8   
PSILOCYBIN AND DEPRESSION  
Amanda Fielding, founder of the Beckley Foundation and known researcher of 
psychedelic medicine, conducted a study using psilocybin in the treatment of chronic 
depression which showed that 67% of participants, who had been depressed for eighteen 
years on average and had been unresponsive to every other form of treatment, 
experienced significant improvement in their symptoms one week later. Three months 
later 42% remained depression free, a remarkably high success rate.6 Another study 
recorded how two experiences with psilocybin improved depression scores for weeks, 
and in some people, years,9 positioning it as one of the most powerful therapeutics for 
treatment-resistant depression.5 In most studies, the psychedelic is given just once, in 
some twice or three times over weeks, as part of an ongoing psychotherapy course, in 
complete contrast to currently available medications, most are given at least daily, often 
with limited therapeutic support.5 This breakthrough treatment offers the possibility to 
access and remedy underlying biopsychosocial causes of depression unlike standard 
antidepressants that just treat the symptoms by protecting against the stressors that lead 
to and perpetuate depression.  In contrast, psychedelic therapy via the effects of the drugs 
is able to facilitate insight and emotional release and with psychotherapeutic support, a 
subsequent healthy revision of outlook and life- style .12	 
CONCLUSION 
Despite the notion by people of psychedelics as troublesome drugs of abuse, 
present studies demonstrate remarkably beneficial effects that deserve further research.6 
By taking advantage of the medicinal benefits of psilocybin instead of seeing it solely as 
a drug of abuse, we can produce groundbreaking treatments to treat mental disorders 
than commonly contribute to and lead to drug abuse itself. We would be addressing 
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